Detalhe da pesquisa
1.
Real-world operation of multiple sclerosis centres in Central-Eastern European countries covering 107 million inhabitants.
Mult Scler Relat Disord
; 69: 104406, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36413917
2.
Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group.
Wien Med Wochenschr
; 162(15-16): 354-66, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22895849
3.
Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease.
Ther Adv Neurol Disord
; 13: 1756286420975223, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33335562
4.
Clinical, magnetic resonance imaging, cerebrospinal fluid and electrophysiological characteristics of the earliest multiple sclerosis.
Clin Neurol Neurosurg
; 110(3): 233-8, 2008 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-18093725
5.
Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients.
Clin Neurol Neurosurg
; 139: 35-40, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26363365
6.
Interferons beta have vasoconstrictive and procoagulant effects: a woman who developed livedo reticularis and Raynaud phenomenon in association with interferon beta treatment for multiple sclerosis.
Clin Neurol Neurosurg
; 115 Suppl 1: S79-81, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24321162
7.
Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis--result of a pilot randomized, blind study.
Clin Neurol Neurosurg
; 115 Suppl 1: S86-9, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24321164
8.
How does fingolimod (gilenya(®)) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?
Front Neurol
; 4: 10, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23641231